X
[{"orgOrder":0,"company":"Pureos Bioventures","sponsor":"Engimmune Therapeutics","pharmaFlowCategory":"D","amount":"$16.7 million","upfrontCash":"Undisclosed","newsHeadline":"Engimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-cell Receptor Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Pureos Bioventures","sponsor":"PulseSight Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Pureos Bioventures
Filters
Companies By Therapeutic Area
Details:
PST-809, is a potential first-in-class therapy for wet age-related macular degeneration that comprises a dual-gene plasmid encoding for anti-VEGF, aflibercept, together with decorin.
Lead Product(s):
PST-809
Therapeutic Area: Ophthalmology
Product Name: PST-809
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Recipient:
PulseSight Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 27, 2024
Details:
Proceeds from the financing will be used to further build Engimmune’s pipeline having T-cell receptor based therapies, expand the research team in Switzerland, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
Lead Product(s):
T-cell Receptor Therapeutic
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Cell and Gene therapy
Recipient:
Engimmune Therapeutics
Deal Size: $16.7 million
Upfront Cash: Undisclosed
Deal Type: Financing
May 03, 2022